Correlation Between Alto Neuroscience, and Candel Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Alto Neuroscience, and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alto Neuroscience, and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alto Neuroscience, and Candel Therapeutics, you can compare the effects of market volatilities on Alto Neuroscience, and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alto Neuroscience, with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alto Neuroscience, and Candel Therapeutics.

Diversification Opportunities for Alto Neuroscience, and Candel Therapeutics

-0.46
  Correlation Coefficient

Very good diversification

The 3 months correlation between Alto and Candel is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Alto Neuroscience, and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Alto Neuroscience, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alto Neuroscience, are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Alto Neuroscience, i.e., Alto Neuroscience, and Candel Therapeutics go up and down completely randomly.

Pair Corralation between Alto Neuroscience, and Candel Therapeutics

Given the investment horizon of 90 days Alto Neuroscience, is expected to under-perform the Candel Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Alto Neuroscience, is 2.87 times less risky than Candel Therapeutics. The stock trades about -0.06 of its potential returns per unit of risk. The Candel Therapeutics is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  451.00  in Candel Therapeutics on December 3, 2024 and sell it today you would earn a total of  340.00  from holding Candel Therapeutics or generate 75.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Alto Neuroscience,  vs.  Candel Therapeutics

 Performance 
       Timeline  
Alto Neuroscience, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Alto Neuroscience, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Candel Therapeutics 

Risk-Adjusted Performance

OK

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Alto Neuroscience, and Candel Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Alto Neuroscience, and Candel Therapeutics

The main advantage of trading using opposite Alto Neuroscience, and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alto Neuroscience, position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.
The idea behind Alto Neuroscience, and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets